Mr. Ron Schmitz reports

GLOBAL UAV ANNOUNCES PROPOSED ACQUISITION OF NEXUS PEPTIDE SCIENCES INC.

Global UAV Technologies Ltd. has entered into a letter of intent (LOI) dated July 27, 2026, with Nexus Peptide Sciences Inc., a private corporation existing under the laws of British Columbia, pursuant to which the company would acquire all of the outstanding securities of Nexus from the securityholders of Nexus.

About Nexus Peptide Sciences Inc.

Nexus Peptide Sciences is a private biotechnology company, based in Vancouver, B.C. Nexus is developing optimized peptide formulations and next-generation delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications.

Peptides are short chains of amino acids that act as native signalling molecules, regulating metabolism, repair, immunity and cognition. Nexus's platform is directed at what the company identifies as the principal constraint on peptide adoption -- the molecule itself and the route of delivery -- as most peptides degrade rapidly, struggle to cross biological barriers and require injection to remain stable.

Nexus's work spans five areas: molecular optimization (sequence and structural refinement to improve stability, half-life and target selectivity); formulation chemistry (excipient and carrier systems engineered for solubility, shelf stability and consistent dosing); researching optimal delivery systems (needle-free formats, including transdermal patches, oral platforms and absorption-enhanced carriers); quality and verification (manufacturing in approved facilities with batch-level third party analytical testing for identity, purity and contamination); and regulatory alignment (monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based products).

Further information regarding Nexus, its business, its programs and its financial position will be included in the listing statement to be prepared in connection with the transaction and filed under the company's profile on SEDAR+.

Summary of the transaction

The LOI is a non-binding agreement that sets out the principal terms on which the parties have agreed to complete the transaction. Subject to satisfactory due diligence and successful additional negotiations, the parties intend to enter into a definitive agreement with respect to the transaction on or before Aug. 31, 2026. The transaction is considered a fundamental change pursuant to the policies of the Canadian Securities Exchange, requiring the CSE to review and approve the transaction. The transaction is an arm's-length transaction.

On completion of the transaction, the company has agreed to issue an aggregate of 20.3 million common shares in the capital of the company and seven million transferable share purchase warrants of the company to the Nexus shareholders on a pro rata basis. Each warrant is exercisable into one additional share at an exercise price of 10 cents per warrant share for a period of two years following the closing in consideration for the acquisition of all of the securities of Nexus. Immediately before the closing, Global UAV has agreed that there will be no more than 33 million shares and 17 million share purchase warrants issued and outstanding, with such warrants to have an exercise price of 10 cents per share. At the time of closing, Nexus will become a wholly owned subsidiary of the company. If issued, the shares and warrants may be subject to certain restrictions on transfer pursuant to the requirements of applicable law. The company anticipates that there will be a finder's fee in connection with the transaction comprising $100,000 in cash and one million shares.

The transaction will be completed pursuant to available exemptions under applicable legislation. The company may pay a finder's fee in connection with the transaction.

Concurrent financing

On or before the closing of the transaction, the company intends to complete an equity financing of a minimum of $3-million and a maximum of $5-million.

Board and management

On closing of the transaction, the board of directors of the combined company will consist of five directors -- three nominees of Nexus (Dr. Patrick Gunning, Dr. Mark Lindsay and Dr. Mona Ezzat-Velinov) and two continuing directors of the company (Ron Schmitz and Tim Ko). The company anticipates that, on closing, Chris Cherry will be appointed as chief financial officer. Additional information on the proposed directors, officers and insiders (as defined in the policies of the CSE) of the resulting issuer will be included in subsequent press releases in connection with the transaction.

Dr. Gunning -- proposed director and chief scientific officer

Dr. Gunning is a professor of molecular therapeutics at the University of Glasgow and a professor of chemistry at the University of Toronto and was previously a Canada research chair in medicinal chemistry and founder and inaugural director of the Centre for Medicinal Chemistry. He earned his PhD from the University of Glasgow and completed postdoctoral studies at Yale University. He has written over 140 research publications and is a fellow of the Royal Society of Chemistry; his recognitions include the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship and Canada's Top 40 Under 40. Dr. Gunning has co-founded multiple biotechnology companies, including Janpix Inc., Centessa Pharmaceuticals, Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics and Carnyx Therapeutics.

Dr. Lindsay -- proposed director

Dr. Lindsay is a doctor of chiropractic and a graduate of Palmer Chiropractic College, with 35 years of experience working with elite athletes, including Super Bowl, Stanley Cup and MLB (Major League Baseball) championship teams and Olympic and world champions. He is a diplomate of the American Chiropractic Neurology Board and a member of the Ontario and Colorado chiropractic associations and is a PhD candidate in the neuroscience program at Queen's University. He has completed over 3,000 hours of graduate study in neurology through the Carrick Institute for Graduate Studies, is the author of Fascia: Clinical Applications for Health and Human Performance and 10 research publications, and serves as a research fellow at the Steadman Philippon Research Institute in Vail, Colo. He is a co-founder of Carnyx Therapeutics, Kelvin Therapeutics and Entourage AI.

Dr. Ezzat-Velinov -- proposed director

Dr. Ezzat-Velinov is a board-certified family physician with more than 25 years of clinical experience specializing in integrative and functional medicine and works in longevity medicine. She has provided expertise to health care and technology organizations, including Apple, Facebook, One Medical, Human Longevity and Fountain Life, is a frequent conference speaker including at the Buck Institute, and has written published chapters on integrative wellness and women's longevity. She is a member of the American Academy of Family Physicians, the Institute for Functional Medicine and the Mast Cell Academy.

Mr. Cherry -- proposed chief financial officer

Mr. Cherry has over 20 years of corporate accounting and audit experience and has held senior positions with several public mining companies, including director, chief financial officer and secretary. He is a CPA, having obtained the chartered accountant designation in 2009 and the certified general accountant designation in 2004. He previously held positions with KPMG and Davidson & Co. LLP in Vancouver, auditing junior public companies.

Mr. Schmitz -- continuing director, president and chief executive officer

Mr. Schmitz has been a director, chief executive officer and chief financial officer of numerous public companies since 1997 and is an active participant in the junior markets. Mr. Schmitz is also the president of ASI Accounting Services Inc., which has provided administrative, accounting and office services to public and private companies since 1995.

Mr. Ko -- continuing director

Mr. Ko is an entrepreneur who has successfully founded and operated businesses in technology and biotech. He has served at both the executive and board levels and has overseen the successful financing, acquisition and operations of businesses in his time within the Canadian public markets.

Completion of the transaction remains subject to a number of conditions, including satisfactory due diligence, entry into a definitive agreement, completion of audited financial statements for Nexus, the receipt of all requisite approvals required to consummate the transaction and other conditions customary for transactions of this nature. The LOI includes a completion deadline of Aug. 31, 2026. The parties will endeavour to complete the transaction as soon as practicable and intend to complete the transaction prior to the completion deadline. There can be no assurance that the transaction will be completed as proposed or at all.

Completion of the transaction is subject to a number of conditions, including acceptance of the CSE. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the company should be considered highly speculative.

We seek Safe Harbor.